Professor J. Richard Harvey, Jr., a leading expert on offshore tax operations by US multinational corporations, was recently quoted in The New York Times (May 12) and the Wall Street Journal (May 2 and May 11) about the now-abandoned proposal for a Pfizer takeover of U.K.-based AstraZeneca and his prediction that the IRS would delay its enforcement of FATCA (Foreign Account Tax Compliance Act).
Harvey is a Distinguished Professor of Practice at Villanova University School of Law and its Graduate Tax Program, where he teaches courses including Tax Policy, Corporate Tax Transparency and Accounting for Lawyers.
A former IRS advisor with over 35 years of multifaceted tax experience, Harvey helped to write the FATCA legislation and is often called upon by leading media outlets for his expert commentary on the matter. In May 2013, he testified before the U.S. Senate Permanent Subcommittee on the offshore tax practices of Apple, Inc.
Regarding Pfizer’s proposed reincorporation in the United Kingdom, which hinged on the huge tax savings it might have generated, Harvey is quoted in the New York Times as saying, “Given all of the existing loopholes in U.S. tax law, I am not sure whether Pfizer will really save that much in U.S. taxes. Rather, the expatriation will likely make Pfizer’s life a lot easier from a treasury/financing perspective.”
To view Harvey’s complete bio, click here.